Related Experiment Video
Updated: Aug 12, 2026
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
Identification of Potential Therapeutic Targets and Drugs for Depression: A Genome-Wide Druggable Mendelian
Zehua Luo1, Jiaqian Ma2, Fan Wu1
1Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Introduction:
Depression is a common and complex mental health condition. It is shaped by many genetic, environmental, and social factors that influence when it starts and how it progresses. The main biological changes behind depression are still not well understood. Current treatments help some patients, but many only experience partial or unstable benefits. There is a clear need for treatments that are both more effective and more precise for depression. In this study, up-to-date genetic and pharmacogenomic data were used to identify genes targeted by drugs and potential therapy targets for depression. Information from several independent resources was brought together, and these datasets were combined in a stepwise way. With this strategy, the aim was to provide a practical starting point for the development of more targeted antidepressant therapies.
Methods:
Cross-tissue expression quantitative trait loci (eQTL) were first used to analyze data, and these data were combined with Genome-Wide Association Study (GWAS) summary statistics for depression. Then Mendelian Randomization (MR) was applied to identify candidate druggable genes. Colocalization analyses were also performed to check whether the eQTL and depression signals were likely to share the same causal variants. To further assess biological and therapeutic relevance, Phenome-Wide Association Studies (PheWAS), functional enrichment analyses, computational drug prediction, molecular docking, and molecular dynamics simulations were carried out.
Results:
Using Mendelian randomization, 34 blood-derived genes and 25 brain-derived genes were identified that showed evidence of association with depression. Colocalization further supported causal roles for 23 blood-and 14 brain-derived genes, with SNRK, MANF, and P4HTM showing significant signals in both tissues. Enrichment analyses implicated immune-related pathways. Docking and dynamics confirmed stable binding between key targets and compounds such as quercetagetin and myricetin.
Discussion:
In this study, 34 potential druggable targets for depression were found, with SNRK, MANF, and P4HTM showing consistent importance across tissues. In addition, quercetagetin and myricetin emerged as promising candidates for depression therapy.
Conclusion:
These findings provide new therapeutic candidates and help establish a mechanistic framework for the development of targeted antidepressants.
Insights
This study identified 34 potential druggable targets for depression, including SNRK, MANF, and P4HTM. Natural compounds like quercetagetin and myricetin show promise for developing more effective, targeted antidepressant therapies.
Area of Science:
- Genetics and Pharmacogenomics
- Neuroscience
- Computational Biology
Background:
- Depression is a complex mental health disorder influenced by genetic, environmental, and social factors.
- Current depression treatments offer limited efficacy for many patients, highlighting the need for novel therapeutic strategies.
- Understanding the biological underpinnings of depression is crucial for developing precise and effective interventions.
Purpose of the Study:
- To identify novel druggable genes and potential therapeutic targets for depression using integrated genetic and pharmacogenomic data.
- To establish a framework for developing more targeted and effective antidepressant therapies.
- To explore natural compounds as potential candidates for depression treatment.
Main Methods:
- Cross-tissue expression quantitative trait loci (eQTL) analysis combined with Genome-Wide Association Study (GWAS) data for depression.
- Mendelian Randomization (MR) to identify candidate druggable genes and colocalization analyses to confirm shared causal variants.
- Phenome-Wide Association Studies (PheWAS), functional enrichment, drug prediction, molecular docking, and molecular dynamics simulations to assess biological and therapeutic relevance.
Main Results:
- Identified 34 blood-derived and 25 brain-derived genes associated with depression via Mendelian Randomization.
- Confirmed causal roles for 23 blood- and 14 brain-derived genes, with SNRK, MANF, and P4HTM showing significant cross-tissue signals.
- Immune-related pathways were implicated, and molecular docking/dynamics confirmed binding of quercetagetin and myricetin to key targets.
Conclusions:
- Discovered 34 potential druggable targets for depression, emphasizing SNRK, MANF, and P4HTM for their consistent importance.
- Identified quercetagetin and myricetin as promising therapeutic candidates for depression.
- Provided a mechanistic framework and novel targets for the development of next-generation antidepressants.
More Related Videos
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
01:21G-protein Coupled Receptors
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
01:26Drug Discovery: Overview
01:23Antidepressant Drugs: MAOIs and Other Agents
01:29Pharmacogenomics: Identification of New Drug Targets